Skip to main content

Fluidigm Licenses Protein Crystallization Technology from Syrrx

NEW YORK, Feb. 3 (GenomeWeb News) - Microfluidics developer Fluidigm has obtained non-exclusive license rights to Syrrx's submicroliter protein crystallization technology, the companies said today.

The terms of the licensing agreement were not disclosed.

Syrrx said it obtained "broad patent protection" for the crystallization of proteins in submicroliter volumes through an exclusive license with Lawrence Berkeley National Laboratory. Fluidigm's non-exclusive license will provide it with freedom to operate relative to Syrrx's patent portfolio, the companies said.

Fluidigm said it acquired the license to support the commercialization of its Topaz protein crystallization platform, which relies on chips that consume only nanogram quantities of protein per trial.

David Weitz, Syrrx's general counsel, said in a statement that Fluidigm is the first system manufacturer to license the company's technology, and that Syrrx "looks forward to securing other licensees as submicroliter crystallization is more widely adopted."

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.